---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134796"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:47:47.133141+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q1 net loss $26.9M; bitopertin AURORA trial misses primary endpoint, but shows secondary benefits

## Summary
- Cash and cash equivalents $342.6M at March 31, 2024; provides runway well into 2026.
- Net loss $26.9M in Q1 2024 vs. $22.8M in Q1 2023; R&D expense rose to $23.7M from $20.2M.
- Bitopertin AURORA phase 2 in EPP: significant PPIX reduction; missed primary endpoint (light tolerance) due to placebo benefit; 60mg dose showed significant reduction in phototoxic pain reactions.
- Received FDA Rare Pediatric Disease Designation for bitopertin in EPP in May 2024.
- On track to present additional AURORA/BEACON data, initial DISC-3405 SAD data, and updated DISC-0974 MF data in Q2 2024.

## SEC filing metadata
- accession: 0001193125-24-134796
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/0001193125-24-134796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/d827802d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134796
- JSON: https://secwatch.observer/filing/0001193125-24-134796.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134796.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $26.9 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss was $26.9 million
  - Result: reported results
  source text: Disc Medicine, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/0001193125-24-134796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.